RCT | Safety of Fezolinetant for vasomotor symptoms associated with menopause
17 Apr, 2023 | 12:54h | UTCRelated:
RCT | Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause
RCT | Efficacy of Fezolinetant in moderate-to-severe vasomotor symptoms associated with menopause